Angiogenesis
Angiogenesis is the growth of new blood vessels from the existing vasculature. This process is involved in development, wound healing, embryo formation and tumor growth. Activation of angiogenesis leads to the release of pro-angiogenic growth factors such as VEGF, PDGF, FGF and TGF, which bind their receptors on endothelial cells within pre-existing vessels. As a result, it induces signal transduction of various pathways such as PI3K/Akt, Erk1/2, Smad and Notch, causing endothelial cells proliferation and migration. Endothelial cells use matrix metalloproteases and integrins to digest extracellular matrix and migrate into new area, where they lengthen and form tubes, generating new blood vessel.
During tumor angiogenesis, cancer cells stimulate formation of new blood vessel for delivering oxygen and nutrients to a tumor. As the tumor grows, cells at the center of the mass become starved of oxygen, causing hypoxia. It stabilizes the expression of a transcription factor, HIF-1α (hypoxia inducible factor-1), which binds HIF-1β to upregulate the expression of several angiogenesis-promoting genes. Moreover, growth factor signaling also stimulates HIF-1 activity in order to maintain oxygen homeostasis for growing cells.
- B5952 LFM-A13Summary: BTK特异性酪氨酸激酶抑制剂
- B5851 FG2216Target: Pyruvate dehydrogenases (PDH)Summary: HIF-脯氨酰羟化酶抑制剂
- B4862 CWHM-12Summary: αV整联蛋白抑制剂
- B5770 Leukadherin 1Summary: CD11b/CD18激活剂
- B5631 TC-I 15Summary: α2β1整联蛋白抑制剂
- B5492 TCS 2314Summary: 整合素极晚期抗原-4(VLA-4;α4β1)拮抗剂
- B7741 BIO 51921 CitationSummary: α4β1抑制剂
- B7157 OGT 2115Target: HeparanasesSummary: 乙酰肝素酶抑制剂
- B6764 Combretastatin A4中文名: 康普立停 A4Summary: 微管蛋白聚合抑制剂
- B6664 GR 144053 trihydrochlorideSummary: 血小板纤维蛋白原受体糖蛋白IIb/IIIa(GpIIb/IIIa)拮抗剂